PE20070592A1 - Derivados de prolinamida como moduladores de canales de sodio - Google Patents
Derivados de prolinamida como moduladores de canales de sodioInfo
- Publication number
- PE20070592A1 PE20070592A1 PE2006001225A PE2006001225A PE20070592A1 PE 20070592 A1 PE20070592 A1 PE 20070592A1 PE 2006001225 A PE2006001225 A PE 2006001225A PE 2006001225 A PE2006001225 A PE 2006001225A PE 20070592 A1 PE20070592 A1 PE 20070592A1
- Authority
- PE
- Peru
- Prior art keywords
- prolinamide
- sodium channel
- channel modulators
- fluorophenyl
- phenyl
- Prior art date
Links
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical class NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 title abstract 2
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- -1 4 - {(2-FLUOROPHENYL) METHYL OXY} PHENYL Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002996 emotional effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
SE REFIERE AL COMPUESTO 5-(4-{(2-FLUOROFENIL)METIL OXI}FENIL)PROLINAMIDA DE FORMULA (I), Y SUS DIASTEROISOMEOS SIENDO PREFERIDO (5R)-5-(4-{[(2-FLUOROFENIL)METIL]OXI}FENIL)-L-PROLINAMIDA EN FORMA CRISTALINA. TAMBIEN SE REFIERE A PROCEDIMIENTOS DE PREPARACION Y UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE. ESTOS COMPUESTOS SON MODULADORES DE LOS CANALES DE SODIO CON APERTURA POR VOLTAJE, POR LO QUE SON UTILES EN EL TRATAMIENTO DE DEPRESION, TRASTORNOS DEL ESTADO EMOCIONAL O TRASTORNO BIPOLAR
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0520581A GB0520581D0 (en) | 2005-10-10 | 2005-10-10 | Novel compounds |
GB0523045A GB0523045D0 (en) | 2005-11-11 | 2005-11-11 | Novel compounds |
GB0603900A GB0603900D0 (en) | 2006-02-27 | 2006-02-27 | Novel compounds |
GB0618336A GB0618336D0 (en) | 2006-09-18 | 2006-09-18 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070592A1 true PE20070592A1 (es) | 2007-06-23 |
Family
ID=37546777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001225A PE20070592A1 (es) | 2005-10-10 | 2006-10-06 | Derivados de prolinamida como moduladores de canales de sodio |
Country Status (20)
Country | Link |
---|---|
US (2) | US7655693B2 (es) |
EP (1) | EP1934177B8 (es) |
JP (1) | JP5139305B2 (es) |
KR (1) | KR101282464B1 (es) |
AR (1) | AR056575A1 (es) |
AT (1) | ATE556049T1 (es) |
AU (1) | AU2006301470B2 (es) |
BR (1) | BRPI0616944B8 (es) |
CA (1) | CA2625642C (es) |
CR (1) | CR9898A (es) |
EA (1) | EA015736B1 (es) |
ES (1) | ES2387405T3 (es) |
IL (1) | IL192627A0 (es) |
MA (1) | MA29817B1 (es) |
NO (1) | NO20082145L (es) |
NZ (1) | NZ567051A (es) |
PE (1) | PE20070592A1 (es) |
PL (1) | PL1934177T3 (es) |
TW (1) | TW200730494A (es) |
WO (1) | WO2007042239A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8143306B2 (en) * | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
EP1943216B1 (en) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
JP2013501026A (ja) * | 2009-08-05 | 2013-01-10 | クオンベルゲンセ プハルマセウトイカルス リミテッド | てんかん及び関連疾患の治療のための共治療法 |
PT2477964E (pt) | 2009-09-14 | 2015-06-04 | Convergence Pharmaceuticals | Processo para a preparação de derivados de alfa-carboxamida |
EP3009427B1 (en) | 2011-03-03 | 2019-12-18 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
WO2015130905A1 (en) | 2014-02-27 | 2015-09-03 | Merck Patent Gmbh | Heterocyclic compounds as nav channel inhibitors and uses thereof |
GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
WO2016102967A1 (en) * | 2014-12-23 | 2016-06-30 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
JP2019537601A (ja) * | 2016-11-02 | 2019-12-26 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 新規投薬レジメン |
EP3634400A4 (en) * | 2017-05-19 | 2021-06-09 | Biogen MA Inc. | NEW CRYSTALLINE SHAPES |
KR20200061381A (ko) * | 2017-10-05 | 2020-06-02 | 바이오젠 인크. | 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정 |
JP2020536898A (ja) | 2017-10-10 | 2020-12-17 | バイオジェン インコーポレイテッド | スピロ誘導体を調製するためのプロセス |
KR20210002472A (ko) * | 2018-04-16 | 2021-01-08 | 바이오젠 엠에이 인코포레이티드 | 신경병증성 통증을 치료하는 방법 |
EA202192762A1 (ru) * | 2019-04-10 | 2022-03-21 | Байоджен Ма Инк. | Способ получения производных альфа-карбоксамид пирролидина |
JP2022526431A (ja) * | 2019-04-10 | 2022-05-24 | バイオジェン インコーポレイテッド | アルファ-カルボキサミドピロリジン誘導体を調製するためのプロセス |
WO2021154631A1 (en) * | 2020-01-30 | 2021-08-05 | Javed Mohammad | Combination drug therapies for cns disorders |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
US6136131A (en) * | 1998-06-02 | 2000-10-24 | Instrument Specialties Company, Inc. | Method of shielding and obtaining access to a component on a printed circuit board |
CN1353605A (zh) | 1999-03-26 | 2002-06-12 | 欧洲凯尔特股份有限公司 | 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用 |
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
PA8583001A1 (es) | 2002-09-20 | 2004-04-23 | Hoffmann La Roche | Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b |
AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
EP1615895A4 (en) | 2003-04-03 | 2007-11-07 | Merck & Co Inc | SUBSTITUTED BIARYL PYRAZOLES AS SODIUM CHANNEL BLOCKERS |
CN1805945A (zh) | 2003-04-18 | 2006-07-19 | 麦克公司 | 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑 |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
EP1524265A1 (en) | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
WO2005100334A1 (en) | 2004-04-14 | 2005-10-27 | Pfizer Products Inc. | Dipeptidyl peptidase-iv inhibitors |
JP2008540438A (ja) | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリジン |
US7858786B2 (en) | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
WO2006124865A2 (en) | 2005-05-19 | 2006-11-23 | Vertex Pharmaceuticals Incorporated | Biaryls derivatives useful as modulators of ion channels |
CA2621564C (en) | 2005-09-09 | 2014-06-03 | Smithkline Beecham Corporation | Pyridine derivatives and their use in the treatment of psychotic disorders |
EP1943216B1 (en) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
CA2676357A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-10-05 TW TW095136986A patent/TW200730494A/zh unknown
- 2006-10-06 US US11/570,560 patent/US7655693B2/en active Active
- 2006-10-06 CA CA2625642A patent/CA2625642C/en active Active
- 2006-10-06 NZ NZ567051A patent/NZ567051A/en unknown
- 2006-10-06 EP EP06806110A patent/EP1934177B8/en active Active
- 2006-10-06 PE PE2006001225A patent/PE20070592A1/es not_active Application Discontinuation
- 2006-10-06 AT AT06806110T patent/ATE556049T1/de active
- 2006-10-06 BR BRPI0616944A patent/BRPI0616944B8/pt active IP Right Grant
- 2006-10-06 AU AU2006301470A patent/AU2006301470B2/en not_active Ceased
- 2006-10-06 JP JP2008534910A patent/JP5139305B2/ja active Active
- 2006-10-06 PL PL06806110T patent/PL1934177T3/pl unknown
- 2006-10-06 KR KR1020087011271A patent/KR101282464B1/ko active IP Right Grant
- 2006-10-06 EA EA200801054A patent/EA015736B1/ru not_active IP Right Cessation
- 2006-10-06 ES ES06806110T patent/ES2387405T3/es active Active
- 2006-10-06 WO PCT/EP2006/009731 patent/WO2007042239A1/en active Application Filing
- 2006-10-09 AR ARP060104441A patent/AR056575A1/es not_active Application Discontinuation
-
2008
- 2008-03-31 MA MA30797A patent/MA29817B1/fr unknown
- 2008-04-18 CR CR9898A patent/CR9898A/es not_active Application Discontinuation
- 2008-05-07 NO NO20082145A patent/NO20082145L/no not_active Application Discontinuation
- 2008-07-03 IL IL192627A patent/IL192627A0/en active IP Right Grant
-
2009
- 2009-12-17 US US12/641,111 patent/US8153681B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5139305B2 (ja) | 2013-02-06 |
BRPI0616944A2 (pt) | 2011-07-05 |
NZ567051A (en) | 2011-03-31 |
WO2007042239A1 (en) | 2007-04-19 |
KR101282464B1 (ko) | 2013-07-04 |
EP1934177B8 (en) | 2012-09-05 |
KR20080059296A (ko) | 2008-06-26 |
BRPI0616944B1 (pt) | 2020-04-14 |
ES2387405T3 (es) | 2012-09-21 |
AU2006301470B2 (en) | 2012-06-14 |
ATE556049T1 (de) | 2012-05-15 |
AR056575A1 (es) | 2007-10-10 |
US7655693B2 (en) | 2010-02-02 |
PL1934177T3 (pl) | 2013-03-29 |
CA2625642A1 (en) | 2007-04-19 |
CA2625642C (en) | 2013-12-24 |
EP1934177A1 (en) | 2008-06-25 |
JP2009511519A (ja) | 2009-03-19 |
EA015736B1 (ru) | 2011-10-31 |
US20080280969A1 (en) | 2008-11-13 |
US20100105754A1 (en) | 2010-04-29 |
IL192627A0 (en) | 2011-08-01 |
MA29817B1 (fr) | 2008-09-01 |
BRPI0616944B8 (pt) | 2021-05-25 |
AU2006301470A1 (en) | 2007-04-19 |
EA200801054A1 (ru) | 2008-08-29 |
US8153681B2 (en) | 2012-04-10 |
EP1934177B1 (en) | 2012-05-02 |
CR9898A (es) | 2008-07-29 |
NO20082145L (no) | 2008-05-07 |
TW200730494A (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070592A1 (es) | Derivados de prolinamida como moduladores de canales de sodio | |
ATE472529T1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
PE20090888A1 (es) | Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119 | |
CR11470A (es) | Compuestos organicos | |
PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
EA200901617A1 (ru) | Борсодержащие молекулы небольшого размера | |
CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
CY1112921T1 (el) | Ενεργοποιητες γλυκοκινασης πυρρολιδινονης | |
PE20090730A1 (es) | Derivados de piridina como moduladores de los canales de sodio | |
ECSP099621A (es) | Derivados de ciclohexano espirociclico | |
ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
EA201001848A1 (ru) | Производные пиразина в качестве блокаторов эпителиальных натриевых каналов | |
ECSP088221A (es) | Agonistas adrenoreceptores alfa2c | |
CL2011000159A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona, inhibidores de 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes. | |
UY29486A1 (es) | Compuestos utiles en terapia | |
ECSP10010273A (es) | Tratamiento de plantas de plátano y papa con una nueva composición antifúngica | |
AR057869A1 (es) | Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto | |
BRPI0924617A8 (pt) | Compostos heterociclicos de fenoximetila | |
PA8855001A1 (es) | Monocarbamas | |
AR065714A1 (es) | Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida | |
PE20080207A1 (es) | DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5 | |
CL2009001328A1 (es) | Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor. | |
PE20090953A1 (es) | Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace | |
AR106180A2 (es) | COMPUESTO DE a-AMINOCARBOXIAMIDA QUE ES 5-(4-{[(2-FLUOROFENIL)METIL]OXI}FENIL)PROLINAMIDA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |